CTLT - Catalent, Inc.
| Previous Close | 53.98 |
| Open | 53.81 |
| Bid | 53.56 x 900 |
| Ask | 53.70 x 1300 |
| Day's Range | 53.57 - 53.92 |
| 52 Week Range | 29.23 - 55.98 |
| Volume | 31,290 |
| Avg. Volume | 835,464 |
| Market Cap | 7.838B |
| Beta (3Y Monthly) | 1.81 |
| PE Ratio (TTM) | 51.42 |
| EPS (TTM) | 1.05 |
| Earnings Date | Aug 26, 2019 - Aug 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 52.11 |
- Zacks•yesterday
CTLT vs. ZTS: Which Stock Is the Better Value Option?
CTLT vs. ZTS: Which Stock Is the Better Value Option?
- Motley Fool•4 days ago
Here's Why Catalent Stock Soared 73.9% in the First Half of 2019
Gene therapies, here we come.
- Business Wire•7 days ago
Catalent Extends Global Commercial Spray Drying Capabilities in Europe
Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies, and development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has significantly expanded the capacity of its global spray drying operations through an agreement with Sanofi Active Ingredient Solutions, an industrial platform of Sanofi, under which Sanofi will provide Catalent with access to spray drying manufacturing services for Catalent’s customers at Sanofi’s Haverhill, U.K. facility.
- American City Business Journals•19 days ago
Novavax selling manufacturing business amid good news for flu vaccine
The biotech will turn over two of its Gaithersburg manufacturing facilities and equipment to Paragon Bioservices Inc., now part of New Jersey-based Catalent Inc.
- Business Wire•22 days ago
Catalent Announces Pricing of Private Offering of Senior Unsecured Notes Due 2027
Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), priced a private offering (the “Private Offering”) of $500.0 million in aggregate principal amount of 5.00% senior unsecured notes due 2027 (the “Notes”) at par. The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses and (iii) provide cash on its balance sheet for general corporate purposes.
- Moody's•22 days ago
Catalent Pharma Solutions, Inc. -- Moody's assigns B3 rating to Catalent's notes offering
The proposed offering does not have a material effect on Catalent's financial leverage, which Moody's approximates is 5x on a pro forma basis for the recent acquisition of Paragon Bioservices. Catalent's liquidity will be supported by free cash flow in excess of $150 million over the next year, a strong cash balance ($228 million as of March 31, 2019) and its $550 million revolving credit facility.
- Business Wire•22 days ago
Catalent Announces Launch of Private Offering of $500 Million of Senior Unsecured Notes Due 2027
Catalent, Inc. (“Catalent”) (CTLT), the leading global diversified provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that its wholly owned subsidiary, Catalent Pharma Solutions, Inc. (the “Operating Subsidiary”), intends to offer, subject to market and other conditions, $500 million in aggregate principal amount of senior unsecured notes due 2027 (the “Notes”) in a private offering (the “Private Offering”) that is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”). The Operating Subsidiary intends to use the net proceeds from the Private Offering to (i) repay in full the outstanding borrowings under its U.S. dollar-denominated term loans that mature in May 2024 under its senior secured credit facilities, plus any accrued and unpaid interest thereon, (ii) pay related fees and expenses, and (iii) provide cash on its balance sheet for general corporate purposes.
- Insider Monkey•23 days ago
Did Hedge Funds Drop The Ball On Catalent Inc (CTLT) ?
We can judge whether Catalent Inc (NYSE:CTLT) is a good investment right now by following the lead of some of the best investors in the world and piggybacking their ideas. There's no better way to get these firms' immense resources and analytical capabilities working for us than to follow their lead into their best ideas. […]
- Zacks•27 days ago
Catalent (CTLT) Upgraded to Buy: What Does It Mean for the Stock?
Catalent (CTLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
- Business Wire•27 days ago
Catalent to Purchase Bristol-Myers Squibb Manufacturing Facility in Anagni, Italy
Bristol-Myers Squibb Company (BMY) and Catalent, Inc. (CTLT), today announced that Catalent has agreed to purchase Bristol-Myers Squibb’s oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. Catalent is the leading global provider of advanced delivery technologies, development and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products.
- Markit•last month
See what the IHS Markit Score report has to say about Catalent Inc.
Catalent Inc NYSE:CTLTView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for CTLT with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding CTLT totaled $49 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Business Wire•2 months ago
Catalent, Inc. to Present at the Jefferies Healthcare Conference
Catalent, Inc. , the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, Senior Vice President & Chief Financial Officer, will present at the Jefferies Healthcare Conference at 3:00 p.m.
- Zacks•2 months ago
Catalent Acquires Gene Therapy Leader Paragon Bioservices
Catalent (CTLT) acquires gene therapy leader Paragon Bioservices for $1.2 billion.
- Business Wire•2 months ago
Catalent Completes Acquisition of Gene Therapy Leader Paragon Bioservices, Inc. for $1.2 Billion
Catalent, Inc. (CTLT), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it has completed the $1.2 billion acquisition of Paragon Bioservices, Inc., a leading viral vector development and manufacturing partner for gene therapies. With the addition of Paragon’s specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used vector to deliver DNA to cells, Catalent is positioned to capitalize on strong industry tailwinds in the potentially $40 billion addressable market for gene therapies.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of CTLT earnings conference call or presentation 7-May-19 12:15pm GMT
Q3 2019 Catalent Inc Earnings Call
- Moody's•2 months ago
Catalent Pharma Solutions, Inc. -- Moody's downgrades Catalent's senior secured rating to Ba3, affirms B1 CFR rating; the outlook remains stable
Moody's Investors Service ("Moody's") downgraded Catalent Pharma Solutions, Inc. ("Catalent")'s senior secured credit ratings to Ba3 from Ba2. At the same time, Moody's affirmed Catalent's B1 Corporate Family Rating (CFR), the B1-PD Probability of Default Rating, and the B3 senior unsecured rating.
Motley Fool•2 months agoCatalent Inc (CTLT) Q3 2019 Earnings Call Transcript
CTLT earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Catalent (CTLT) Surpasses Q3 Earnings Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 8.89% and -4.14%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Catalent: Fiscal 3Q Earnings Snapshot
The Somerset, New Jersey-based company said it had net income of 22 cents per share. Earnings, adjusted for one-time gains and costs, were 49 cents per share. The results topped Wall Street expectations. ...
- Business Wire•2 months ago
Catalent, Inc. Reports Third Quarter Fiscal 2019 Results
SOMERSET, N.J.-- -- Q3'19 revenue of $617.5 million decreased 2% as-reported, but increased 2% in constant currency, from Q3'18, while Q3'19 YTD revenue of $1,792.3 million increased 1% as-reported, or 3% in constant currency, from the prior-year period. Double-digit organic segment EBITDA growth within Biologics and Specialty Drug Delivery, Oral Drug Delivery and Clinical Supply Services segments; ...
- Zacks•3 months ago
Catalent (CTLT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Moody's•3 months ago
Catalent Pharma Solutions, Inc. -- Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Catalent Pharma Solutions, Inc. New York, April 17, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Catalent Pharma Solutions, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
- Moody's•3 months ago
Catalent Pharma Solutions, Inc. -- Moody's: Catalent's acquisition of Paragon will increase leverage, a credit negative
New York, April 17, 2019 -- Moody's Investors Service ("Moody's") commented that Catalent Pharma Solutions, Inc.'s proposed acquisition of Paragon Bioservices for $1.2 billion in cash will increase the company's financial leverage, a credit negative. For additional information please refer to Moody's Issuer Comment on Catalent Pharma Solutions available on www.moodys.com. Headquartered in Somerset, New Jersey, Catalent Pharma Solutions, Inc. is a leading provider of development solutions and advanced delivery technologies for drugs, biologics and consumer health products.
